Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Hematology

How Often Are Repeat Bone Marrow Biopsies Needed for ET?

At a Glance

After essential thrombocythemia is diagnosed, stable patients usually do not need bone marrow biopsies on a regular schedule. Hematologists typically use blood counts, exams, and symptoms for follow-up, repeating a biopsy only when concerning changes need explanation.

You do not need to get bone marrow biopsies on a regular, scheduled basis for the rest of your life [1][2].

While a bone marrow biopsy is critical for your initial diagnosis—to confirm essential thrombocythemia (ET) and rule out similar conditions like prefibrotic myelofibrosis—routine, calendar-based biopsies (such as getting one every year) are not the standard of care once your disease is stable [3][4].

Instead of regular biopsies, your hematologist will monitor you using routine blood tests (like a complete blood count, or CBC), physical exams, and conversations about your symptoms [5][2]. The frequency of your clinic visits and lab draws will be personalized. You might be seen every few months if you recently started a new medication, or less frequently if your blood counts and symptoms remain steady.

Changes That Prompt Further Evaluation

ET is a chronic condition, but it can sometimes progress to other blood disorders, such as post-ET myelofibrosis (increasing scar tissue in the bone marrow) or, rarely, acute leukemia [6][7]. If your care team notices certain changes in your health or lab results, they will want to investigate.

A repeat biopsy is usually considered only when the care team needs to see what is happening inside the bone marrow to explain these clinical changes [8][9]. Changes that warrant further evaluation include:

  • Unexplained New Anemia or Cytopenias: A significant, persistent drop in your red blood cells (anemia) or platelets (thrombocytopenia) that isn’t explained by medication, bleeding, or a nutritional deficiency [8].
  • A Newly Enlarged Spleen (Splenomegaly): If the bone marrow becomes scarred, the body sometimes shifts blood cell production to the spleen (a process called extramedullary hematopoiesis), causing it to swell [9]. You might notice pain in your upper left abdomen or feel full very quickly when eating.
  • Shifting White Blood Cell Patterns: While a mildly high white blood cell count is common in ET, a rapidly increasing count, or the appearance of blasts (very immature blood cells that belong in the marrow, not the bloodstream), requires prompt hematology review [9].
  • Persistently Elevated LDH Levels: LDH (lactate dehydrogenase) is an enzyme released when cells are damaged or rapidly dividing. While it can rise for many benign reasons, a persistently increasing LDH trend can be an early signal of disease evolution [8].
  • New or Worsening Constitutional Symptoms: These are severe, whole-body symptoms, such as profound new fatigue, drenching night sweats, unexplained weight loss, or persistent low-grade fevers [8][9].

What These Changes Mean

Developing one of these signs does not automatically mean your ET has progressed [10]. Many of these findings can be caused by other factors. For example, certain ET medications (like hydroxyurea) can alter your blood counts, and common infections can temporarily increase your white blood cells and LDH levels [10].

A biopsy is just one tool in a broader diagnostic workup. If your doctor recommends one, the results will be combined with other tests—such as a review of your blood smear, iron/B12 levels, and physical exam—to distinguish between a medication side effect, an unrelated health issue, or true disease progression [11][12]. Your hematologist might also suggest a biopsy if there is uncertainty about your original diagnosis.

When to Seek Immediate Care

Because ET increases your risk of blood clots and bleeding, do not wait for a routine visit if you experience sudden or severe symptoms. Seek urgent or emergency medical care if you experience:

  • Sudden weakness, numbness, or changes in speech or vision (potential signs of a stroke)
  • Severe chest pain or shortness of breath
  • A newly painful, swollen, or red leg (potential signs of a deep vein thrombosis)
  • Unusual or uncontrolled bleeding

Common questions in this guide

Are annual bone marrow biopsies needed for essential thrombocythemia?
Usually not. A bone marrow biopsy is important for confirming the initial diagnosis and distinguishing ET from similar disorders, but routine calendar-based biopsies are not standard when the disease is stable. Follow-up usually uses blood counts, physical exams, and symptom review.
What changes can lead to a repeat bone marrow biopsy in ET?
A hematologist may consider another biopsy when persistent, unexplained anemia or low blood counts, a newly enlarged spleen, changing white blood cell patterns or very immature blood cells, a steadily rising LDH level, or new severe fatigue, night sweats, weight loss, or fevers need explanation. A repeat biopsy can help assess whether the condition has evolved or whether another problem is responsible.
How is essential thrombocythemia monitored without regular biopsies?
Monitoring usually includes complete blood counts, physical exams, and discussion of symptoms. Visits and lab tests may be scheduled every few months after a medication change and less often when blood counts and symptoms remain stable.
Do changing blood counts always mean that ET is progressing?
No. Medication effects, infections, bleeding, and nutritional problems can change blood counts or LDH levels without indicating disease progression. Your hematologist may combine blood-smear review, iron and vitamin B12 testing, physical examination, and trends over time before deciding whether a biopsy is needed.
What emergency symptoms should a person with ET act on right away?
Seek urgent medical care for sudden weakness, numbness, or speech or vision changes; severe chest pain or shortness of breath; a new painful, swollen, red leg; or unusual, uncontrolled bleeding. These symptoms can signal a serious clot, stroke, or bleeding problem and should not wait for a routine appointment.
What should I ask if my doctor recommends another biopsy?
Ask what specific question the biopsy is meant to answer and how the result could change your treatment or monitoring. You can also ask about local anesthetic, pain control, and options to reduce anxiety during the procedure.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific question would a repeat biopsy answer, and how would the results change my treatment plan?
  2. 2.How often will we be checking my blood counts, and what specific trends are you watching for in my labs?
  3. 3.If my blood counts start to change, what steps will we take to determine if it is a side effect of my medication versus disease progression?
  4. 4.If a biopsy is ever recommended in the future, what options do we have for pain control, local anesthetics, or anxiety relief during the procedure?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Tracking fibrosis in myeloproliferative neoplasms by CCR2 expression on CD34+ cells.

    Pozzi G, Carubbi C, Gobbi G, et al.

    Frontiers in oncology 2022; (12()):980379 doi:10.3389/fonc.2022.980379.

    PMID: 36072806
  2. 2

    Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

    Gerds AT, Gotlib J, Ali H, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(9)):1033-1062.

    PMID: 36075392
  3. 3

    Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification.

    Thiele J, Kvasnicka HM, Gianelli U, et al.

    Blood cancer journal 2025; (15(1)):31 doi:10.1038/s41408-025-01235-7.

    PMID: 40038244
  4. 4

    The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.

    Thiele J, Kvasnicka HM, Orazi A, et al.

    American journal of hematology 2023; (98(1)):166-179 doi:10.1002/ajh.26751.

    PMID: 36200127
  5. 5

    Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

    Mesa R, Jamieson C, Bhatia R, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2016; (14(12)):1572-1611 doi:10.6004/jnccn.2016.0169.

    PMID: 27956542
  6. 6

    Myelodysplastic syndrome with fibrosis and complex karyotype arising in a patient with essential thrombocythaemia.

    Mansor NA, Yusof N, Tang YL, et al.

    The Malaysian journal of pathology 2018; (40(2)):191-197.

    PMID: 30173238
  7. 7

    Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

    Rumi E, Cazzola M

    Blood 2017; (129(6)):680-692 doi:10.1182/blood-2016-10-695957.

    PMID: 28028026
  8. 8

    Development and validation of a model for the early prediction of progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: a multicentre retrospective study.

    Xiang D, Yang X, Qian H, et al.

    EClinicalMedicine 2024; (67()):102378 doi:10.1016/j.eclinm.2023.102378.

    PMID: 38188688
  9. 9

    Diagnosis and management of prefibrotic myelofibrosis.

    Rumi E, Sant'Antonio E, Boveri E, et al.

    Expert review of hematology 2018; (11(7)):537-545 doi:10.1080/17474086.2018.1484280.

    PMID: 29862872
  10. 10

    Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms.

    Pich A, Beggiato E, Godio L, et al.

    Expert review of hematology 2021; (14(9)):841-850 doi:10.1080/17474086.2021.1967138.

    PMID: 34384330
  11. 11

    Unexpected melanoma metastasis with E-cadherin expression in bone marrow.

    Pocci M

    Journal of hematopathology 2026; (19(1)).

    PMID: 42360677
  12. 12

    Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

    Gisslinger H, Jeryczynski G, Gisslinger B, et al.

    Leukemia 2016; (30(5)):1126-32 doi:10.1038/leu.2015.360.

    PMID: 26710883

This page is for informational purposes only and does not constitute medical advice about repeat bone marrow biopsies for essential thrombocythemia. Your hematologist should determine the right follow-up schedule and whether testing is needed for your situation.

Get notified when new evidence is published on Essential thrombocythemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.